e-learning
resources
Madrid 2019
Monday, 30.09.2019
Real-world experience of monoclonal antibodies in asthma
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Analysis of two-year treatment with omalizumab patients with severe asthma in real clinical practice
E. Blinova (Chelyabinsk, Russian Federation), G. Ignatova (Chelyabinsk, Russian Federation)
Source:
International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Session:
Real-world experience of monoclonal antibodies in asthma
Session type:
Thematic Poster
Number:
2514
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. Blinova (Chelyabinsk, Russian Federation), G. Ignatova (Chelyabinsk, Russian Federation). Analysis of two-year treatment with omalizumab patients with severe asthma in real clinical practice. 2514
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Real life study showing the epidemiological profile and adherence to treatment of patients with severe allergic asthma in use of omalizumab in the past year.
Source: International Congress 2018 – Biomarkers for evaluating asthma
Year: 2018
Predictors of response to therapy with omalizumab in patients with severe allergic asthma–a real life study
Source: International Congress 2017 – Monitoring asthma control
Year: 2017
Treatment eligibility of mepolizumab-treated severe asthma patients in clinical practice
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Physician assessment of asthma control in patients receiving omalizumab in a real-world setting
Source: Annual Congress 2012 - Asthma treatment: efficacy and safety
Year: 2012
Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey
Source: Eur Respir J 2013; 42: 1224-1233
Year: 2013
Cost analysis for patients with severe asthma receiving omalizumab treatment
Source: International Congress 2019 – Clinical aspects of airway diseases
Year: 2019
Patients’ perception of allergic asthma and their compliance to omalizumab in an Italian clinical setting
Source: International Congress 2017 – Asthma management
Year: 2017
Real life experience with omalizumab and mepolizumab in severe asthma : do patient baseline features preclude effectiveness comparison ?
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Step-down of moderate-severe asthma treatment in clinical practice
Source: International Congress 2018 – Asthma management
Year: 2018
Inflammatory biomarkers in the evaluation of two-year outcomes of omalizumab treatment in severe allergic asthma.
Source: International Congress 2018 – Biomarkers for evaluating asthma
Year: 2018
Evaluating the efficacy of omalizumab in severe persistent asthma patients
Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies
Year: 2017
The use of omalizumab in the management of severe chronic paediatric asthma
Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma
Year: 2008
Omalizumab decreases medical resource utilisation in patients with severe allergic asthma in an Italian real-life setting
Source: International Congress 2017 – Asthma management
Year: 2017
Physicians judge add-on omalizumab therapy as an effective treatment for patients with severe persistent allergic asthma: a pooled analysis
Source: Eur Respir J 2005; 26: Suppl. 49, 49s
Year: 2005
Predictors of effectiveness of omalizumab treatment in patients with severe asthma recruited in a real-life setting
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015
The APEX study: A retrospective review of outcomes in patients with severe allergic asthma who were or were not hospitalised in the year prior to omalizumab initiation in UK clinical practice
Source: Annual Congress 2012 - Clinical aspects and treatment of asthma and allergic respiratory diseases
Year: 2012
Stop omalizumab: a multicenter follow up study after discontinuation in pediatric patients with severe asthma
Source: Virtual Congress 2021 – Paediatric allergic asthma: novel therapeutics and monitoring approaches
Year: 2021
Effect of omalizumab on the risk of hospitalisation in patients with uncontrolled severe asthma in real-life. The PAX-LASER cohort
Source: Annual Congress 2010 - Aspects of severe asthma
Year: 2010
Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009
Which patients should be treated with anti-IgE?
Source: Eur Respir Rev 2007; 16: 85-87
Year: 2007
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept